Value of CT tumor volume measurement parameters combined with laboratory indexes in guiding preoperative staging prediction in patients with colon cancer

doi:10.3877/cma.j.issn.2095-2015.2024.04.004

Abstract

Abstract:

Objective

To analyze the application value of CT tumor volume measurement parameters combined with preoperative laboratory indexes in preoperative staging prediction.

Methods

A total of 75 patients with colon cancer admitted in Feicheng People's Hospital from March 2021 to September 2023 were selected. Taking the pathological examination results as the gold standard, the patients were divided into stage Ⅰ-Ⅱ group and stage Ⅲ-Ⅳ group according to pTNM stages. The parameters of CT tumor volume, including tumor length (Tlen), tumor maximum diameter (Tdia), tumor maximum area (Tare) and tumor volume (Tvol), were measured, and their blood lipids, coagulation indexes and serum albumin (ADL) were detected, and lactate dehydrogenase to albumin ratio (LAR) was calculated. The different indexes of patients with different pTNM stages of colon cancer were summarized, the area under the curve (AUC) of each index to evaluate colon cancer stages individually and jointly were drawn using receiver operating characteristic curve (ROC), and the predictive efficiency was calculated.

Results

Among 75 patients with colon cancer, there were 11 cases in stage Ⅰ, 25 cases in stage Ⅱ, 33 cases in stage Ⅲ and 6 cases in stage Ⅳ. There was no significant difference in baseline data between stage Ⅰ-Ⅱ and stage Ⅲ-Ⅳ groups (P>0.05). Tlen, Tdia, Tare and Tvol in stage Ⅰ-Ⅱ group were lower than those in stage Ⅲ-Ⅳ group (P<0.05). There was no significant difference in blood lipid levels between stage Ⅰ-Ⅱ and stage Ⅲ-Ⅳ groups (P>0.05). The coagulation indexes (PT, APTT, FIB and D-D) and LAR in Ⅰ-Ⅱ stage group were lower than those in Ⅲ-Ⅳ stage group (P<0.05). The AUC of predicting the staging of colon cancer patients by combining all the indexes was 0.880, and the sensitivity and specificity were 94.44% and 82.05%, respectively.

Conclusion

The progress of staging of colon cancer patients is accompanied by the changes of CT tumor volume measurement parameters, coagulation indexes and LAR. The combination of the above indexes can provide reliable reference for preoperative staging prediction.

Key words: Colon cancer, Tumor volume, Blood lipids, Coagulation, Albumin, Stages

Wenyuan Zhao, Yuting Tian, Jihai Zhang, Jun Zhang. Value of CT tumor volume measurement parameters combined with laboratory indexes in guiding preoperative staging prediction in patients with colon cancer[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(04): 306-309.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2024.04.004

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2024/V14/I04/306

Figures/Tables 5

References 17

[12]	李亚男, 熊枝繁, 周琦, 等. 外周血纤维蛋白原,血小板与淋巴细胞比值,癌胚抗原在老年结直肠癌中的预测作用研究[J]. 临床内科杂志, 2022, 39(9): 602-606.
[13]	Uludag SS, Sanli AN, Zengin AK, et al. Systemic inflammatory biomarkers as surrogate markers for stage in colon cancer[J]. Am Surg, 2022, 88(6): 1256-1262.
[14]	杜希剑, 余开湖, 章凯敏. 术前高分辨率MRI评估T3期直肠癌新辅助治疗效果[J]. 中国介入影像与治疗学, 2021, 18(9): 548-552.
[15]	Osterman E, Ekström J, Sjöblom T, et al. Accurate population-based model for individual prediction of colon cancer recurrence[J]. Acta Oncol, 2021, 60(10): 1241-1249.
[16]	Lin X, Zhao S, Jiang H, et al. A radiomics-based nomogram for preoperative T staging prediction of rectal cancer[J]. Abdom Radiol, 2021, 46(10): 4525-4535.
[17]	Goiffon RJ, O'Shea A, Harisinghani MG. Advances in radiological staging of colorectal cancer[J]. Clin Radiol, 2021, 76(12): 879-888.
[1]	Olsen ASF, Gundestrup AK, Kleif J, et al. Accuracy of preoperative staging with multidetector computed tomography in colon cancer[J]. Colorect Dis, 2021, 23(3): 680-688.
[2]	Zheng P, Lai C, Yang W, et al. Nomogram predicting cancer-specific survival in elderly patients with stages Ⅰ-Ⅲ colon cancer[J]. Scand J Gastroenterol, 2020, 55(2): 202-208.
[3]	祖亮, 王祖飞, 陈炜越, 等. 18F-FDG-PET/CT联合MRI在预测结直肠癌术前TN分期中的临床价值[J]. 温州医科大学学报, 2021, 51(12): 968-973.
[4]	Hong EK, Landolfi F, Castagnoli F, et al. CT for lymph node staging of Colon cancer: not only size but also location and number of lymph node count[J]. Abdom Radiol, 2021, 46(9): 4096-4105.
[5]	Zhou Y, Han Z, Dou F, et al. Pre-colectomy location and TNM staging of colon cancer by the computed tomography colonography: a diagnostic performance study[J]. World J Surg Oncol, 2021, 19(1): 1-13.
[6]	张茗昱, 杨吉刚, 王振常. 18F-FDG PET/CT代谢参数评估结直肠癌TNM分期的应用研究[J]. 临床和实验医学杂志, 2020, 19(14): 1474-1478.
[7]	Dai W, Mo S, Xiang W, et al. The critical role of tumor size in predicting prognosis for T1 colon cancer[J]. Oncologist, 2020, 25(3): 244-251.
[8]	Dai W, Mo S, Han L, et al. Prognostic and predictive value of radiomics signatures in stage Ⅰ-Ⅲ colon cancer[J]. Clin Tansl Med, 2020, 10(1): 288-293.
[9]	廖乐恩, 潘志忠. 结直肠癌精准外科的综合诊疗[J]. 中国癌症防治杂志, 2023, 15(4): 361-369.
[10]	Karamchandani DM, Chetty R, King TS, et al. Challenges with colorectal cancer staging: results of an international study[J]. Modern Pathol, 2020, 33(1): 153-163.
[11]	邱丽, 谭翠莲, 刘华. 术前NLR, PLR联合血清肿瘤标志物评估结直肠癌患者预后的临床价值[J]. 中国普通外科杂志, 2020, 29(12): 1533-1538.

组别	例数	年龄(岁,±s)	性别[例(%)]		病灶部位[例(%)]			组织学类型[例(%)]
组别	例数	年龄(岁,±s)	男	女	升结肠	横结肠	其他	腺癌	其他
Ⅰ~Ⅱ期组	36	60.95±5.25	23(63.89)	13(36.11)	15(41.67)	12(33.33)	9(25.00)	28(77.78)	8(22.22)
Ⅲ~Ⅳ期组	39	61.33±5.41	24(61.54)	15(38.46)	19(48.72)	10(25.64)	10(25.64)	31(79.49)	8(20.51)
t/χ²值		0.308	0.044		0.586			0.033
P值		0.759	0.833		0.746			0.857

组别	例数	年龄(岁,±s)	性别[例(%)]		病灶部位[例(%)]			组织学类型[例(%)]
组别	例数	年龄(岁,±s)	男	女	升结肠	横结肠	其他	腺癌	其他
Ⅰ~Ⅱ期组	36	60.95±5.25	23(63.89)	13(36.11)	15(41.67)	12(33.33)	9(25.00)	28(77.78)	8(22.22)
Ⅲ~Ⅳ期组	39	61.33±5.41	24(61.54)	15(38.46)	19(48.72)	10(25.64)	10(25.64)	31(79.49)	8(20.51)
t/χ²值		0.308	0.044		0.586			0.033
P值		0.759	0.833		0.746			0.857

组别	例数	Tlen(cm)	Tdia(cm)	Tare(cm²)	Tvol(cm³)
Ⅰ~Ⅱ期组	36	4.29±0.67	1.53±0.38	8.89±1.23	25.66±5.29
Ⅲ~Ⅳ期组	39	6.17±0.89	2.08±0.46	16.17±1.54	56.81±8.91
t值		10.268	5.619	22.499	18.216
P值		<0.001	<0.001	<0.001	<0.001

组别	例数	Tlen(cm)	Tdia(cm)	Tare(cm²)	Tvol(cm³)
Ⅰ~Ⅱ期组	36	4.29±0.67	1.53±0.38	8.89±1.23	25.66±5.29
Ⅲ~Ⅳ期组	39	6.17±0.89	2.08±0.46	16.17±1.54	56.81±8.91
t值		10.268	5.619	22.499	18.216
P值		<0.001	<0.001	<0.001	<0.001

组别	例数	TC(mmol/L)	TG(mmol/L)	HDL-C(mmol/L)	LDL-C(mmol/L)	PT(s)	APTT(s)
Ⅰ~Ⅱ期组	36	4.51±0.19	1.44±0.12	1.30±0.08	2.47±0.13	13.65±1.59	36.81±3.52
Ⅲ~Ⅳ期组	39	4.56±0.22	1.45±0.19	1.32±0.06	2.52±0.19	17.81±2.81	46.71±4.89
t值		1.049	0.270	1.231	1.319	7.802	9.989
P值		0.297	0.788	0.222	0.191	<0.001	<0.001
组别	例数	FIB(g/L)	D-D(mg/L)	LDH(U/L)	ALB(g/L)	LAR
Ⅰ~Ⅱ期组	36	5.17±0.36	0.47±0.11	171.83±26.95	40.15±4.76	4.28±0.43
Ⅲ~Ⅳ期组	39	7.22±1.51	1.08±0.26	224.69±31.38	40.04±4.91	5.61±0.69
t值		7.936	13.036	7.795	0.098	9.920
P值		<0.001	<0.001	<0.001	0.922	<0.001

Please choose a citation manager

Content to export